Sorrento Therapeutics Stock Latest News

Sorrento Therapeutics (SRNE) has plans to shortly advance its Bruton’s tyrosine kinase (Btk) inhibitor abivertinib into pivotal testing...

Shares of Sorrento Therapeutics (SRNE) have been on the backfoot for most of the year, retreating by 63%...

Sorrento Therapeutics (SRNE) revealed impressive results from an independent real-world study by INMEGEN (The Institute of National Genomics...

Sorrento Therapeutics, Inc. (SRNE) is a clinical-stage biopharmaceutical company developing new cancer treatment therapies. It’s also developing potential...

Sorrento Therapeutics (NASDAQ: SRNE), a clinical-stage, antibody-centric biopharmaceutical company, received the go-ahead to commence the Phase 1 clinical...

It looks like the pandemic isn’t behind us yet. The alarming rise in Covid-19 cases has coincided with...

Osteoarthritis is a degenerative joint disease which affects millions of people across the globe, and according to Wiseguy...

Sorrento Therapeutics (SRNE) is a company with its foot on the gas, and hardly a week goes by...

Shares of the biopharmaceutical company Sorrento Therapeutics (SRNE) jumped 5.1% in Friday’s extended trading session after the company...

Anyone keeping track of the progress being made at Sorrento Therapeutics (SRNE), will be aware the company has...

The developments are coming in thick and fast at Sorrento Therapeutics (SRNE). Recent times have seen a flurry...

Sorrento Therapeutics’ subsidiary, Scilex Holding, has received approval from the US Food and Drug Administration (FDA) for its...

Sorrento (SRNE) is not a company to rest on its laurels, particularly on the acquisition front. There have...

Shares of Sorrento Therapeutics increased 3.3% to close at $8.27 on April 5 after the clinical-stage antibody-centric biopharmaceutical...

Once a specialist in oncology drugs and pain management, last year, Sorrento Therapeutics (SRNE) refocused its business on...

Sorrento (SRNE) has a multi-pronged approach to therapeutics. The company has been constantly adding new options to its...

Not content with boasting a pipeline bursting at the seams with multiple candidates in various stages of development,...

Diversifying a portfolio is often cited as a safe investing strategy, but it is also the game plan...

Some companies favor a “do one job and do it well” approach. However, that is not the Sorrento...

The major U.S. equity-indexes are hovering around all-time highs, and a question that frequently pops up these days,...

Shares of Sorrento Therapeutics spiked 8% in Wednesday’s pre-market trading after the drugmaker filed for emergency use of...

Shares in Sorrento rose 2.7% in Monday’s extended market session after the company entered into an exclusive license...

Once a specialist in oncology drugs and pain management, Sorrento Therapeutics (SRNE) has pivoted to attack COVID-19 head-on...

Sorrento Therapeutics (SRNE) has taken a unique approach to fighting the coronavirus. While most pharma companies taking the...

Shares in Sorrento Therapeutics (SRNE) spiked 10.51% in Tuesday’s trading after the company released positive Phase 1b Study results...

Shares in Sorrento are surging 28% in Thursday’s pre-market session after the biotech company said it received US...

The coronavirus has thrust many previously unknown pharma companies into the spotlight. You can certainly place Sorrento Therapeutics...

Sorrento Therapeutics (SRNE) and SmartPharm Therapeutics have now signed a merger agreement for Sorrento to acquire SmartPharm, a...

Sorrento sank 14% in extended market trading after the biotech company announced the ousting of its chief financial...

Anywhere you turn, COVID-19’s impact can be seen. The deadly virus’ romp around the world and the lockdowns...

Sorrento Therapeutics (SRNE) enjoyed yet another stellar day. Sure, there have been plenty of good weeks so far...

Sorrento (SRNE) has signed of a letter of intent to buy SmartPharm, to develop a pipeline of gene-encoded...

A journey of a thousand miles begins with a single step, and a big one in this case....

Diversification is a tried-and-true strategy when investing in stocks. Drug maker Sorrento Therapeutics (SRNE) is applying the same...

Shares in Sorrento Therapeutics (SRNE) edged 5% higher in Friday’s after-hours trading, after the company announced that it...

Shares in Sorrento (SRNE) are rallying 17% in Thursday’s pre-market trading after the company announced that an Application...

Sorrento Therapeutics’ (SRNE) competitors might be further down the line with their COVID-19 programs, but H.C. Wainwright analyst...

Will a single antibody be enough to stomp out a COVID-19 infection? Sorrento Therapeutics (SRNE) says no. Rather,...

And the W’s just keep on coming for Sorrento Therapeutics (SRNE). Reflecting a major step forward in the...

How do we protect those at the frontline facing COVID-19 head on? Sorrento Therapeutics (SRNE) is on it....

Head back to Thursday’s market close and shares of drug maker Sorrento Therapeutics (SRNE) were trading for $2.62,...